GMV Trading 2020, page-15

"China’s health care market still has much room to grow due to the country’s ongoing demographic shift, with the country’s elderly population above the age of 65 estimated to increase from 166 million in 2018 to 250 million by 2030. And as more people move to urban areas, and the number of affluent families rises, health care costs will also increase. However, China’s provision of health care is extremely unbalanced, with more than 2,300 top tier public hospitals running at capacity and struggling to attend to almost 20 per cent of total annual outpatient consultations every year ..."

https://www.scmp.com/economy/china-economy/article/3013976/chinas-fragmented-health-care-system-under-increasing pressure.

"NMPA approval for the Prizma device will allow for the commencement of G Medical’s commercial sales and services activities within the Chinese market. NMPA approval for the manufacture of the Company’s medical devices has already been granted for its Guangzhou production facility, leaving it well positioned to capitalise once NMPA approval for the Prizma device is granted." Company announcement 17 Jan. 2020.

Difficult not to get excited. GLTAH!